Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Squalamine granted fast track status for wet AMD

Oct. 7, 2004

Therapeutic benefits of omalizumab in allergy conjunctivitis

Oct. 6, 2004

Approvable letter for SnET2 for AMD

Oct. 5, 2004

ISTA and Allergan sign new Vitrase agreement

Oct. 4, 2004

Expanded phase II trial for squalamine opens enrollment

Oct. 1, 2004

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

The EMEA accepts marketing authorization application for Macugen

Sep. 23, 2004

Approvable letter for Extravan for glaucoma

Sep. 21, 2004

Novel VAP-1 inhibitors and their use in macular edema described by Fujisawa

Sep. 15, 2004

Sirna Therapeutics files IND to advance Sirna-027 into clinic

Sep. 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...